Recipharm
Recipharm AB, a leading contract development and manufacturing organisation (CDMO), is headquartered in Sweden (SE) and operates extensively across Europe, North America, and Asia. Founded in 1995, Recipharm has established itself as a key player in the pharmaceutical industry, specialising in the development and production of complex drug formulations, including sterile and non-sterile products. The company offers a diverse range of services, from drug development and manufacturing to packaging and analytical services, catering to both small biotech firms and large pharmaceutical companies. Recipharm's commitment to quality and innovation has earned it a strong market position, with notable achievements in expanding its global footprint and enhancing its technological capabilities. With a focus on sustainability and efficiency, Recipharm continues to set benchmarks in the CDMO sector, making it a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does Recipharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recipharm's score of 72 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recipharm's reported carbon emissions
In 2024, Recipharm reported total carbon emissions of approximately 22773000 kg CO2e for Scope 1, 1600000 kg CO2e for Scope 2, and 183618000 kg CO2e for Scope 3. This represents a slight decrease in Scope 1 emissions from 24216000 kg CO2e in 2023, while Scope 2 emissions also decreased from 3193000 kg CO2e. However, Scope 3 emissions increased from 179203000 kg CO2e in the previous year. Recipharm has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 30% by 2025 from a 2020 baseline. Additionally, the company has committed to achieving net-zero emissions for Scope 1 and Scope 2 by 2040 and 2030, respectively. For Scope 3 emissions, Recipharm targets a reduction of 25% by 2030 from a 2021 baseline. The company has also validated its near-term targets through the Science Based Targets initiative (SBTi), committing to a 42.1% reduction in absolute Scope 1 and 2 GHG emissions by 2030, alongside a commitment to source 100% renewable electricity by the same year. These targets align with industry standards to limit global warming to 1.5°C. Recipharm's emissions data and climate commitments reflect its proactive approach to sustainability and its dedication to reducing its environmental impact in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,442,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,517,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 463,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Recipharm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
